CDC Website CDC Website

To Join the NPIN community or

Home » Heart, Lung, and Blood Co-morbiditieS Implementation Models in People Living with HIV (HLB SIMPLe) (UG3/UH3 - Clinical Trial Optional)

Heart, Lung, and Blood Co-morbiditieS Implementation Models in People Living with HIV (HLB SIMPLe) (UG3/UH3 - Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) seeks grant applications to optimally and sustainably address late-stage implementation research questions to address the delivery of proven-effective prevention and treatment interventions for heart, lung, blood, and sleep (HLBS) comorbid diseases and disorders in people living with HIV (PLHIV) in World Bank designated low- and middle-income countries (LMICs) and Small Island Developing States (SIDS). For the purposes of this FOA, late-stage implementation research is defined as research to identify strategies to achieve sustainable uptake of proven-effective interventions in routine clinical, public health, and community-based settings and maximize the positive impact on population health. Each awarded project is to conduct late-stage implementation research within one or more of the following geographical regions: East Asia and the Pacific, Europe and Central Asia, Latin America and the Caribbean, Middle East and North Africa, South Asia, and Sub-Saharan Africa. As a group, awardees will constitute a collaborative alliance for HLBS late-stage (T4) implementation research on comorbid diseases and disorders in PLHIV in LMICs with capabilities for answering research questions (within and across regions) aimed at improving population health outcomes. This FOA is intended to support research that, while carried out in LMICs, results in outcomes that apply to low-resource settings globally. As such, Foreign Institutions are eligible and encouraged to apply. This FOA utilizes a bi-phasic, milestone-driven cooperative agreement (UG3/UH3) mechanism consisting of a study start-up and needs assessment (UG3) phase with possible transition to an implementation (UH3) phase. Awards made under this FOA will support a maximum project period of 5 years, consisting of a 1-2 year UG3 phase and 3-4 year UH3 phase, based on the needs of the proposed research.

Letter of Intent Date
11/10/19
Application Due Date
12/10/19
Project Start Date
7/1/20
Application Contact
Lynn
Rundhaugen
Grants Management Contact
United States
301-480-4546
lr235y@nih.gov
Technical Contact
Brad
Newsome, Ph.D
Program Officer
brad.newsome@nih.gov
United States
301-827-8170
Fund Duration
The scope of the proposed project should determine the project period. The project period is up to 2 years for the UG3 phase and up to 3 years for the UH3 phase. The maximum project period is 5 years.
Subjects
Audiences

Fund Number: 

5506

Fund ID: 

RFA-HL-20-025

Last modified: 

10/2/19